Tech Company Financing Transactions

XTuit Pharmaceuticals Funding Round

On 6/11/2015, XTuit Pharmaceuticals secured $22 million in Series A investment from New Enterprise Associates, Arcus Ventures and CTI Life Sciences Fund.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A
Proceeds Purpose
Proceeds from the financing will be used to advance the development of XTuit's lead products into the clinic in oncology and liver cirrhosis and NASH and to build its biomarker platform which will enable rapid clinical proof-of-concept.

Company Information

Company Status
Private & Independent
Mailing Address
35 Gatehouse Dr. A1
Waltham, MA 02451
Email Address
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response.
XTuit Pharmaceuticals LinkedIn Company Profile
Social Media
XTuit Pharmaceuticals Company Twitter Account
Company News
XTuit Pharmaceuticals News
XTuit Pharmaceuticals on Facebook
XTuit Pharmaceuticals on YouTube

Management Team

Email & Social
Chief Executive Officer
Alan Crane
  Alan Crane LinkedIn Profile  Alan Crane Twitter Account  Alan Crane News  Alan Crane on Facebook
Chief Scientific Officer
Peter Blume-Jensen
  Peter Blume-Jensen LinkedIn Profile  Peter Blume-Jensen Twitter Account  Peter Blume-Jensen News  Peter Blume-Jensen on Facebook



Browse more venture capital transactions:

Prev: 6/11/2015: TripleLift venture capital transaction
Next: 6/12/2015: Bright Funds venture capital transaction


Share this article


About Our VC Transactions Data

We report on funding rounds that are announced publicly. All VC database entries on this site are sourced from a variety of public sources. The information is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary